Share warrant program fully subscribed

XVIVO Perfusion AB's share warrant program 2013/2015 is fully subscribed. A total of 195,000 warrants with the right to subscribe for new shares were issued. Each warrant has in June 2015 the right to subscribe for one new share at a price of SEK 32.40.

The annual shareholder meeting May 7, 2013 approved the warrant program of a maximum of 195,000 warrants to be offered to all employees in XVIVO Perfusion AB. Upon full exercise of the warrants, the share capital increase is SEK 5,070 corresponding to a dilution of about 1 percent of the total number of shares and votes.

Magnus Nilsson, CEO of XVIVO Perfusion: “The broad support is very encouraging and it gives all of our employees a stronger shareholder interest and an even stronger incentive to fulfill our goals.”

July 4, 2013

Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson
CEO

For further information please contact:

Christoffer Rosenblad, CFO, tel: 46 31 788 21 59, e-mail: christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on July 4, 2013 at 4:30 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.